Value of ⁶⁸Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [¹⁸F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.

ABSTRACT:

Objectives

The bombesin derivative RM2 is a GRPr antagonist with strong binding affinity to prostate cancer (PCa). In this study, the impact of [⁶⁸Ga]Ga-RM2 positron emission tomography-computed tomography (PET-CT) for the detection of primary PCa was compared with that of [¹⁸F]FCH PET-CT and multiparametric magnetic resonance imaging (mpMRI).

Methods

This phase I/II study was conducted in 30 biopsy-positive PCa subjects. The patients were stratified into high (10 patients), intermediate (10 patients), and low risk (10 patients) for extraglandular metastases as defined by National Comprehensive Cancer Network (NCCN) criteria (NCCN Clinical Practice Guidelines in Oncology, 2016). The prostate gland was classified in 12 anatomic segments for data analysis

SUBMITTER: Beheshti M 

PROVIDER: S-EPMC9755087 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature